Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin Versus Investigators Choice (IC) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (R/R B-ALL)
نویسندگان
چکیده
منابع مشابه
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Over 90% of leukemic blasts in patients with acute lymphoblastic leukemia express the marker CD22. Inotuzumab ozogamicin (INO) is a CD22-directed humanized monoclonal antibody conjugated to the potent cytotoxin, calicheamicin, via an acid labile linker. INO has shown high rates of response in the treatment of relapsed and refractory (R/R) ALL in single-agent studies, with fewer adverse effects ...
متن کاملProblems and solutions in calculating quality-adjusted life years (QALYs)
The quality-adjusted life-year (QALY) is a measure of the value of health outcomes. Since health is a function of length of life and quality of life, the QALY was developed as an attempt to combine the value of these attributes into a single index number. The QALY calculation is simple: the change in utility value induced by the treatment is multiplied by the duration of the treatment effect to...
متن کاملIncreased soluble HLA-DRB1in B-cell acute lymphoblastic leukaemia.
Soluble HLA (sHLA) are potential tumour markers released in order to counter immune surveillance. sHLA-class II is less known especially in acute lymphoblastic leukaemia (ALL). This study aimed to investigate soluble, surface and allelic expression of HLA Class II (sHLA-DR) in B-cell ALL patients and compare with soluble expression in normal individuals. A sandwich enzyme-linked immunosorbent a...
متن کاملMorphological heterogeneity in childhood B cell acute lymphoblastic leukaemia.
Considerable heterogeneity of lymphoblast morphology in childhood B cell acute lymphoblastic leukaemia has been observed. One case showed unusual monocytic features and emphasised the need for marker studies in the accurate definition of acute lymphoblastic leukaemia phenotypes. B cell acute lymphoblastic leukaemia is rare but may have been previously underestimated by morphological misinterpre...
متن کاملInotuzumab Ozogamicin Murine Analog–Mediated B-Cell Depletion Reduces Anti-islet Allo- and Autoimmune Responses
B cells participate in the priming of the allo- and autoimmune responses, and their depletion can thus be advantageous for islet transplantation. Herein, we provide an extensive study of the effect of B-cell depletion in murine models of islet transplantation. Islet transplantation was performed in hyperglycemic B-cell-deficient(μMT) mice, in a purely alloimmune setting (BALB/c into hyperglycem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2017
ISSN: 1098-3015
DOI: 10.1016/j.jval.2017.08.288